Data safety and monitoring boards for African clinical trials

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 102, Issue 12, 2008, Pages 1189-1194

  Lang, Trudie ^a   Chilengi, Roma ^b   Noor, Ramadhani A ^b   Ogutu, Bernhards ^c,d   Todd, James E ^e   Kilama, Wen L ^b   Targett, Geoffrey A ^f  

^a Wellcome Trust/KEMRI Collaborative Programme   (Kenya)

^b African Malaria Network Trust   (Tanzania)

^c Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Kenya)

^d KEMRI CCR Walter Reed Project   (Kenya)

^e MRC Uganda Research Unit on AIDS   (Uganda)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; Clinical trials data monitoring committees; Data safety monitoring boards; Guidelines; Monitoring; Safety

Indexed keywords

NEW DRUG;

AFRICA; ARTICLE; CLINICAL TRIAL; CURRICULUM DEVELOPMENT; DEVELOPED COUNTRY; DEVELOPING COUNTRY; ENDEMIC DISEASE; FINANCIAL MANAGEMENT; HUMAN; MEDICAL INFORMATION SYSTEM; MEDICAL RESEARCH; METHODOLOGY; PATIENT PARTICIPATION; PERSONNEL SHORTAGE; PRACTICE GUIDELINE; PROCESS MONITORING; QUALITY CONTROL; SAFETY; SKILL; STAFF TRAINING; UNSPECIFIED SIDE EFFECT;

AFRICA; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; GUIDELINES AS TOPIC; HUMANS;

EID: 54949158263     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2008.06.009     Document Type: Article

References (20)

1. Bodil A.N., Wendong C., Christian G., and Lise L.K. Association of funding and conclusions in randomized drug trials. J. Am. Med. Assoc. 290 (2003) 921-928
2. Council for International Organizations of Medical Science. International Ethical Guidelines for Biomedical Research Involving Human Subjects (2002), CIOMS/World Health Organization, Geneva
3. Crawley J., Waruiru C., Mithwani S., Mwangi I., Watkins W., and Ouma D. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 355 (2000) 701-706
4. DeMets D.L., Pocock J.S., and Desmond G.J. The agonizing negative trend in monitoring of clinical trials. Lancet 354 (1999) 1983-1988
5. Ellenberg S., Fleming T., and DeMets D.L. Data monitoring committees in clinical trials: a practical perspective (2002), John Wiley, West Sussex, UK
6. European Medicines Agency, 2005. Committee for Medicinal Products for Human Use: Guideline on Data Monitoring Committees. EMEA, London, EMEA/CHMP/EWP/5872/03.
7. Fawzi W.W., Msamanga G.I., Hunter D., Renjifo B., and Antelman G. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 16 (2002) 1935-1944
8. Fleming R.T., Mccall J., Moore A., Rodgers A., and Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin. Trials 5 (2008) 157-167
9. Glasser S.P., and Howard G. Clinical trials design issues: at least 10 things you should look for in clinical trials. J. Clin. Pharmacol. 46 (2006) 1106-1115
10. Grant A.M., Altman D.G., Babiker A.B., Campbell M.K., Clemens F.J., Derbyshire J.H., Elbourne E.B., Mcleer S.K., Parmar M.K.B., Pocock S.J., Spiegelhalter D.J., Sydes M.R., Walker A.F., Wallace S.A., and DAMOCLES group. Issues in data reporting and interim analysis of trials. Health Technol. Assess. 9 (2005) 1-238
11. Hrobjartsson A., Forfang E., Haahr M.T., Als-Nielsen B., and Brorson S. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int. J. Epidemiol. 36 (2007) 664-665
12. International Conference on Harmonization, Good Clinical Practice, 1996. ICH Harmonized Tripartite Guideline on Good Clinical Practice. World Health Organization, Geneva, ICH/GCP, E6.(R1).
13. Kosorok M.R., Shi Y., and DeMets D.L. Design and analysis of group sequential clinical trials with multiple primary endpoints. Biometrics 60 (2004) 134-145
14. Mills E., Curtis C., Ping W., Beth R., Sonal S., and Gordon H. Randomized trials stopped early for harm in HIV/AIDS: a systematic survey. HIV Clin. Trials 7 (2006) 24-33
15. Montori V.M., Devereaux P.J., Neill K., Adhikari J., Karen E., Burns A., Christoph H.E., Matthias B., Christina L., Teresa W.L., Darling E., Dianne R.M., Bryant M., Heiner C.B., Holger J., Schünemann M.O.M., Deborah J., Cook P.J.E., Amit S., Richa S., Benjamin L., Carly A., Thompson Q.Z., Edward M., and Guyatt G.H. Randomized trials stopped early for benefit: a systematic review. J. Am. Med. Assoc. 294 (2005) 2203-2209
16. Pocock S.J. Size of cancer clinical trials and stopping rules. Br. J. Cancer 38 (1978) 757-766
17. Pocock S.J. Current controversies in data monitoring for clinical trials. Clin. Trials 3 (2006) 513-521
18. USDHHS, 2005. Code of Federal Regulations, Title 45 Public Welfare, Part 46 Protection of Human Subjects. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm [accessed June 2008].
19. Whitehead J. The Design and Analysis of Sequential Clinical Trials (1997), John Wiley, Chichester, UK
20. WHO, 2005. Operational Guidelines for the Establishment and Functioning of Data and Safety Monitoring Boards. World Health Organization, Geneva, WHO/TDR/GEN/Guidelines/05.1.